Fidelity Investments’s Avadel Pharmaceuticals AVDL Stock Holding History

Fidelity Investments’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-10,489	Closed	-$226K	–	5430
2025 Q4	$226K	Sell	10,489 -155,381	-94%	-$3.02M	﹤0.01%	3382
2025 Q3	$2.53M	Buy	165,870 +20,133	+14%	+$262K	﹤0.01%	2463
2025 Q2	$1.29M	Sell	145,737 -75,611	-34%	-$664K	﹤0.01%	2629
2025 Q1	$1.73M	Buy	221,348 +80,585	+57%	+$675K	﹤0.01%	2494
2024 Q4	$1.48M	Buy	140,763 +138,380	+5,807%	+$1.68M	﹤0.01%	2538
2024 Q3	$31.3K	Buy	+2,383	New	+$36.3K	﹤0.01%	3992
2015 Q1	–	Sell	-100,000	Closed	-$1.71M	–	2753
2014 Q4	$1.71M	Sell	100,000 -230,780	-70%	-$3.3M	﹤0.01%	2454
2014 Q3	$4.73M	Sell	330,780 -50,000	-13%	-$719K	﹤0.01%	2247
2014 Q2	$5.71M	Sell	380,780 -112,581	-23%	-$1.36M	﹤0.01%	2206
2014 Q1	$6.61M	Buy	+493,361	New	+$5.29M	﹤0.01%	2139

Other funds holding AVDL

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Fidelity Investments's AVDL Position: Q1 2026 in Review

Fidelity Investments sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 10,489 shares — an estimated $226K sold.

Fidelity Investments first reported a position in AVDL in Q1 2014 and held it in 10 quarters. The position peaked at $6.61M in Q1 2014. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

Fidelity Investments reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Fidelity Investments sold 10,489 Avadel Pharmaceuticals shares in Q1 2026, an estimated $226K.
Fidelity Investments first reported a position in Avadel Pharmaceuticals in Q1 2014 and held it in 10 quarters.
Fidelity Investments's Avadel Pharmaceuticals position peaked at $6.61M in Q1 2014.
2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.